Anti-MUC1 antibody [SM3] (ab22711)
- Datasheet
- References (4)
- Protocols
Overview
-
Product nameAnti-MUC1 antibody [SM3]
See all MUC1 primary antibodies -
DescriptionMouse monoclonal [SM3] to MUC1
-
Host speciesMouse
-
SpecificityThe SM3 monoclonal recognizes the under-glycosylated form of MUC1 and is therefore tumor-specific. Reacts with breast, colon and ovarian cancers. Reacts minimally with normal tissue.
-
Tested applicationsSuitable for: Flow Cyt, IHC-Fr, ICC/IF, ELISA, IHC-Pmore details
-
Species reactivityReacts with: Human
-
Immunogen
Hydrogen fluoride deglycosylated milk mucin.
-
Positive control
- Ovarian, breast or colon carcinoma, normal intestine or colon. IHC-P: FFPE human breast carcinoma ICC-IF: MCF7 cell line.
-
General notes
This antibody clone is manufactured by Abcam.
If you require this antibody in a particular buffer formulation or a particular conjugate for your experiments, please contact orders@abcam.com or you can find further information here.
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
Storage bufferpH: 7.4
Preservative: 0.02% Sodium azide
Constituent: PBS -
Concentration information loading... -
PurityIgG fraction
-
ClonalityMonoclonal
-
Clone numberSM3
-
IsotypeIgG1
-
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab22711 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt | Use 1µg for 106 cells. Requires cell permeabilization. ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
|
| IHC-Fr | Use at an assay dependent concentration. | |
| ICC/IF | Use at an assay dependent concentration. PubMed: 23805168 | |
| ELISA | Use at an assay dependent concentration. | |
| IHC-P | Use a concentration of 5 - 10 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
FunctionThe alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.
The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity. -
Tissue specificityExpressed on the apical surface of epithelial cells, especially of airway passages, breast and uterus. Also expressed in activated and unactivated T-cells. Overexpressed in epithelial tumors, such as breast or ovarian cancer and also in non-epithelial tumor cells. Isoform Y is expressed in tumor cells only.
-
Involvement in diseaseMUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence (PubMed:20816948). Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes.
Medullary cystic kidney disease 1 -
Sequence similaritiesContains 1 SEA domain.
-
Developmental stageDuring fetal development, expressed at low levels in the colonic epithelium from 13 weeks of gestation.
-
Post-translational
modificationsHighly glycosylated (N- and O-linked carbohydrates and sialic acid). O-glycosylated to a varying degree on serine and threonine residues within each tandem repeat, ranging from mono- to penta-glycosylation. The average density ranges from about 50% in human milk to over 90% in T47D breast cancer cells. Further sialylation occurs during recycling. Membrane-shed glycoproteins from kidney and breast cancer cells have preferentially sialyated core 1 structures, while secreted forms from the same tissues display mainly core 2 structures. The O-glycosylated content is overlapping in both these tissues with terminal fucose and galactose, 2- and 3-linked galactose, 3- and 3,6-linked GalNAc-ol and 4-linked GlcNAc predominating. Differentially O-glycosylated in breast carcinomas with 3,4-linked GlcNAc. N-glycosylation consists of high-mannose, acidic complex-type and hybrid glycans in the secreted form MUC1/SEC, and neutral complex-type in the transmembrane form, MUC1/TM.
Proteolytic cleavage in the SEA domain occurs in the endoplasmic reticulum by an autoproteolytic mechanism and requires the full-length SEA domain as well as requiring a Ser, Thr or Cys residue at the P + 1 site. Cleavage at this site also occurs on isoform MUC1/X but not on isoform MUC1/Y. Ectodomain shedding is mediated by ADAM17.
Dual palmitoylation on cysteine residues in the CQC motif is required for recycling from endosomes back to the plasma membrane.
Phosphorylated on tyrosines and serine residues in the C-terminal. Phosphorylation on tyrosines in the C-terminal increases the nuclear location of MUC1 and beta-catenin. Phosphorylation by PKC delta induces binding of MUC1 to beta-catenin/CTNNB1 and thus decreases the formation of the beta-catenin/E-cadherin complex. Src-mediated phosphorylation inhibits interaction with GSK3B. Src- and EGFR-mediated phosphorylation on Tyr-1229 increases binding to beta-catenin/CTNNB1. GSK3B-mediated phosphorylation on Ser-1227 decreases this interaction but restores the formation of the beta-cadherin/E-cadherin complex. On T-cell receptor activation, phosphorylated by LCK. PDGFR-mediated phosphorylation increases nuclear colocalization of MUC1CT and CTNNB1.
The N-terminal sequence has been shown to begin at position 24 or 28. -
Cellular localizationSecreted; Cell membrane. Cytoplasm. Nucleus. On EGF and PDGFRB stimulation, transported to the nucleus through interaction with CTNNB1, a process which is stimulated by phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-catenin at the nucleus and Apical cell membrane. Exclusively located in the apical domain of the plasma membrane of highly polarized epithelial cells. After endocytosis, internalized and recycled to the cell membrane. Located to microvilli and to the tips of long filopodial protusions.
- Information by UniProt
-
Database links
- Entrez Gene: 4582 Human
- Omim: 158340 Human
- SwissProt: P15941 Human
- Unigene: 89603 Human
-
Alternative names
- ADMCKD antibody
- ADMCKD1 antibody
- Breast carcinoma associated antigen DF3 antibody
see all
Images
-
![Flow Cytometry - Anti-MUC1 antibody [SM3] (ab22711)](https://www.abcam.com/ps/products/22/ab22711/Images/ab22711-307433-ab22711FLOW2.jpg)
Flow Cytometry - Anti-MUC1 antibody [SM3] (ab22711)Overlay histogram showing MCF7 cells stained with ab22711 (red line). The cells were fixed with 4% formaldehyde (10 min) and then permeabilized with 0.1% PBS-Triton X-100 for 15 min. The cells were then incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab22711, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150117) at 1/2000 dilution for 30 min at 22°C.
Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab170190, 1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.
This antibody gave a positive signal in MCF7 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Triton X-100 for 15 min used under the same conditions.
-
![Immunocytochemistry/ Immunofluorescence - Anti-MUC1 antibody [SM3] (ab22711)](https://www.abcam.com/ps/products/22/ab22711/Images/ab22711-307017-ab22711AP3318623MCF7m1ugml.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-MUC1 antibody [SM3] (ab22711)ab22711 stained MCF7 cells. The cells were 100% methanol fixed for 5 minutes at -20°C and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1hour at room temperature to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (abxxx at xµg/ml) overnight at +4°C. The secondary antibody (pseudo-colored green) was Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) preadsorbed (ab150117)
used at a 1/1000 dilution for 1hour at room temperature. Alexa Fluor® 594 WGA was used to label plasma membranes (pseudo-colored red) at a 1/200 dilution for 1hour at room temperature. DAPI was used to stain the cell nuclei (pseudo-colored blue) at a concentration of 1.43µM for 1hour at room temperature.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MUC1 antibody [SM3] (ab22711)](https://www.abcam.com/ps/products/22/ab22711/Images/ab22711-281355-ap3373781assy60225Datasheet.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MUC1 antibody [SM3] (ab22711)IHC image of MUC1 staining in a formalin fixed, paraffin embedded human breast carcinoma tissue section*, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab22711, 10 µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MUC1 antibody [SM3] (ab22711)](https://www.abcam.com/ps/products/22/ab22711/Images/MUC1-Primary-antibodies-ab22711-4.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MUC1 antibody [SM3] (ab22711)Image courtesy of an anonymous Abreview.ab22711 staining MUC1 in human breast carcinoma tissue sections by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections). Tissue was fixed with formaldehyde and a heat mediated antigen retrieval step was performed using 10mM citrate buffer. The primary antibody was used undiluted for 18 hours at 4°C. An undiluted HRP-conjugated goat anti-mouse IgG polyclonal was used as secondary antibody.
Protocols
References
This product has been referenced in:
- Lu W et al. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit. Oncotarget 6:34537-48 (2015). Read more (PubMed: 26417929) »
- Geng Y et al. Targeting Underglycosylated MUC1 for the Selective Capture of Highly Metastatic Breast Cancer Cells Under Flow. Cell Mol Bioeng 6:148-159 (2013). Flow Cyt, ICC/IF ; Human . Read more (PubMed: 23805168) »
